NASDAQ:AGEN

Agenus (AGEN) Stock Price, News & Analysis

$6.46
+0.69 (+11.96%)
(As of 04/23/2024 ET)
Today's Range
$5.70
$7.51
50-Day Range
$4.97
$18.56
52-Week Range
$4.78
$42.60
Volume
1.67 million shs
Average Volume
615,866 shs
Market Capitalization
$135.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$130.00

Agenus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,912.4% Upside
$130.00 Price Target
Short Interest
Bearish
227.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.86mentions of Agenus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$325,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($8.21) to ($14.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.03 out of 5 stars

Medical Sector

215th out of 910 stocks

Biological Products, Except Diagnostic Industry

29th out of 153 stocks

AGEN stock logo

About Agenus Stock (NASDAQ:AGEN)

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Stock Price History

AGEN Stock News Headlines

At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
StockNews.com Begins Coverage on Agenus (NASDAQ:AGEN)
Agenus (NASDAQ:AGEN) Sets New 1-Year Low at $8.10
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
AGEN Aug 2024 2.000 put
Earnings Preview For Agenus
AGEN Mar 2024 2.000 put
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/23/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
389
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$130.00
High Stock Price Target
$160.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+1,912.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-245,760,000.00
Net Margins
-164.69%
Pretax Margin
-164.69%

Debt

Sales & Book Value

Annual Sales
$156.31 million
Book Value
($7.78) per share

Miscellaneous

Free Float
19,941,000
Market Cap
$135.34 million
Optionable
Optionable
Beta
1.26
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Founder, Executive Chairman & CEO
    Comp: $1.34M
  • Ms. Christine M. Klaskin (Age 58)
    VP of Finance, Principal Financial Officer & Principal Accounting Officer
    Comp: $407.44k
  • Dr. Steven J. O'Day M.D. (Age 63)
    Ph.D., Chief Medical Officer
    Comp: $970.98k
  • Craig Winter
    Chief Information Officer
  • Mr. Zack Armen
    Head of Investor Relations
  • Ms. Tracy Mazza Clemente
    Chief People Officer
  • Mr. Dhan Chand
    Scientific Director & Head of Drug Discovery
  • Mr. Alfred Dadson
    Chief Manufacturing Officer
  • Mr. Eric Humes
    Chief Quality Officer
  • Dr. Todd Jude Yancey M.D.
    Member of Advisory Board & Chief Strategic Advisor

AGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price target for 2024?

3 equities research analysts have issued twelve-month price objectives for Agenus' stock. Their AGEN share price targets range from $100.00 to $160.00. On average, they predict the company's stock price to reach $130.00 in the next year. This suggests a possible upside of 1,912.4% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2024?

Agenus' stock was trading at $16.5580 at the start of the year. Since then, AGEN stock has decreased by 61.0% and is now trading at $6.46.
View the best growth stocks for 2024 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $2.20. The biotechnology company earned $83.80 million during the quarter, compared to analysts' expectations of $54.21 million.

When did Agenus' stock split?

Shares of Agenus reverse split before market open on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Key Client Fiduciary Advisors LLC (4.10%), Hennion & Walsh Asset Management Inc. (2.67%), Powell Investment Advisors LLC (1.16%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGEN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners